



Sponsor: Sanofi	
Product Code: GZ419828	Product INN: AGALSIDASE BETA
Study Code: LPS15919	EUDRACT Number: 2019-000065-20
Title of the study: A randomized, open-label, active comparator, 2-arm, prospective study to assess the glycosphingolipid clearance and clinical effects of switching to agalsidase beta (Fabrazyme®) versus continuing on migalastat (Galafold®) in male patients with classic Fabry disease	

Study Status: **No patient screened, no patient randomized, no patient exposed to the treatment at the time of the study premature stop.**

Reason of early termination: **The Sponsor terminated the study due to recruitment infeasibility in the context of the covid pandemy and without having been able to enroll any patient in the few months before**